Oncology, skin cancer

Relatlimab and nivolumab in untreated and metastatic melanom

In preclinical models, simultaneous inhibition of LAG-3 and PD-1 showed synergistic antitumor activity. This phase
Breast cancer

Pembrolizumab in treatment of triple-negative breast cance

Pembrolizumab in combination with chemotherapy is already FDA-approved for the treatment of patients with triple-negative
Gynecological Cancer

Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide Carcinosarcoma of the Uterus

This phase III study demonstrates that the combination of paclitaxel and carboplatin is non-inferior to
Gynecological Cancer

Levantinib in combination with pembrolizumab in second line treatment the advanced stage endometrial cancer

Phase III data from the 309- KEYNOTE-775 study demonstrate that the combination of levantinib plus
GI Cancer

Codebreak100 evaluates the efficacy of sotorasib in colorectal cancer previously treated with kras p.g12c mutation

Paper recently published in The Lancet Oncology demonstrates that sotorasib may be a therapeutic strategy
Hematology, Oncology

Zuma-5: long-term follow-up demonstrates substantial and sustained benefit of axicabtagene ciloleucel (axi-cel) for iNHL

Axicabtagene ciloleucel is an autologous anti-CD19 CAR T cell therapy indicated for the treatment of

VISION trial: Radioligand therapy with 177Lu–PSMA-617 for mCRPC

Study shows prolonged imaging-based progression-free survival and overall survival when the radioligand therapy is added
GI: esophagus, Oncology

Prognosis impact of early adjuvant treatment discontinuation in stage III C

A pooled ACCENT/IDEA analysis demonstrates that for patients with stage III colorectal cancer treated with

New dimensions of cancer hallmarks

Cancer hallmarks are a tool for understanding the vast complexity of cancer phenotypes and genotypes.
Breast cancer

Neoadjuvant pembrolizumab plus chemotherapy improves event free survival in early TNBC.

Previous data showed that the addition of pembrolizumab to neoadjuvant chemotherapy led to a significantly
GI: esophagus, Oncology

KEYNOTE – 394: Pembrolizumab in second-line treatment of advanced HCC

The phase 3 study, KEYNOTE-394, demonstrated significant benefit of using pembrolizumab in combination with best
GI Cancer

Choice of first line treatment for advanced hepatocellular carcinoma

In this edition of his monthly column, Tiago Biachi, M.D. Advanced Fellow of Gastrointestinal Oncology
GI Cancer

Advanced Esophageal Squamous-Cell Carcinoma gains new treatment options

For decades, despite the poor survival outcomes, the standard treatment for advanced or metastatic esophageal
GI: esophagus, Oncology

Checkmate 9X8 addition the nivolumab in regimen the first -line treatment of metastatic colorectal cancer

Although the primary endpoint of this phase 2 study was not met, the addition of
Gynecological Cancer, Oncology

Cemiplimab shows survival benefit in patients with cervical cancer

Clinical trial EMPOWER-Cervical 1 demonstrates an overall survival benefit of using cemiplimab as monotherapy, compared